“The subsidiary today has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Gleevec, imatinib mesylate tablets 100mg and 400mg,” says the country’s largest drug maker in its filing.
Subscribe To Our Free Newsletter |